SCHEMBL17430266

SCHEMBL17430266

Oc1ccc2c(c1)C(c1ccnc(F)c1)=NC2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.34
▸ ADORA2B P29275 1/20 0.33
▸ PARP10 Q53GL7 1/20 0.33
▸ PARP11 Q9NR21 1/20 0.33
▸ NFATC1 O95644 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ PBRM1 Q86U86 1/20 0.32
▸ MAP4K4 O95819 1/20 0.31
▸ MINK1 Q8N4C8 1/20 0.31
▸ TNIK Q9UKE5 1/20 0.31
▸ ESR1 P03372 1/20 0.31
▸ ESR2 Q92731 1/20 0.31
▸ CAPN1 P07384 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ RPS6KA3 P51812 1/20 0.31
▸ CA1 P00915 1/20 0.30
▸ CA2 P00918 1/20 0.30
▸ CA7 P43166 1/20 0.30
▸ CA9 Q16790 1/20 0.30
▸ CA14 Q9ULX7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17430280 0.86 KMT2A (0.39) IDO1ADORA2BPARP10PARP11NFATC1
SCHEMBL17430323 0.85 IDO1 (0.35) IDO1ADORA2BPARP10PARP11NFATC1
SCHEMBL17430297 0.83 ADORA2B (0.39) IDO1ADORA2BPARP10PARP11NFATC1
SCHEMBL17430279 0.80 KCNJ1 (0.34) IDO1ADORA2BPARP10PARP11NFATC1
SCHEMBL17430300 0.78 LMNA (0.43) —
SCHEMBL17430307 0.78 MAPK14 (0.35) PARP11
SCHEMBL17916944 0.76 IDO1 (0.36) IDO1ADORA2BNFATC1DYRK1AMAP4K4
SCHEMBL17430268 0.75 LPL (0.39) IDO1PARP10PARP11
SCHEMBL17430293 0.74 ADORA2B (0.36) IDO1ADORA2BPARP10PARP11NFATC1
SCHEMBL17916953 0.73 IDO1 (0.37) IDO1ADORA2BPARP10PARP11NFATC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440952-B2 Compounds inhibiting leucine-rich repeat kinase enzyme activity MERCK SHARP & DOHME CORP. (US) 2016-09-13 — — US disclosed
US-20160009682-A1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY MERCK SHARP & DOHME LLC 2016-01-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009682-A1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY LRRK2, LRRC47, LIMK2 IDO1 1274/4885ADORA2B 4129/4885PARP10 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback